Amarin Corporation and Lotus Pharmaceuticals have entered into significant long-term exclusive partnership to distribute and commercialise VAZKEPA® (icosapent ethyl) in ten countries.
As per the agreement between Amarin Corporation and Lotus Pharmaceuticals, Lotus will have exclusive rights to distribute and carry out commercial promotion for VAZKEPA® in South Korea and nine countries within the Association of Southeast Asian Nations (ASEAN). These countries include Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
Under the terms of agreement, Amarin Corporation will receive an upfront payment, pricing and reimbursement benefits, and sales milestone payments. These payments will be based on the net sales of VAZKEPA® in the regions covered by the agreement.
VAZKEPA® capsules have received approval and have been successfully commercialised in various markets, including the United States and European countries as the first prescription treatment comprised solely of the active ingredient icosapent ethyl, which is a highly purified form of eicosapentaenoic acid (EPA).
This partnership agreement aims to bring innovative and transformative treatments to patients.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!